<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="407">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05155852</url>
  </required_header>
  <id_info>
    <org_study_id>AAAT1562</org_study_id>
    <secondary_id>3K23NS107645-02S1</secondary_id>
    <nct_id>NCT05155852</nct_id>
  </id_info>
  <brief_title>Bedside Monitoring to Identify Impaired Cerebral Autoregulation in Women With Postpartum Hypertension</brief_title>
  <official_title>NIRS-Based Bedside Monitoring to Identify Impaired Cerebral Autoregulation in Women With Postpartum Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to develop a protocol for NIRS-based bedside monitoring&#xD;
      to identify impaired cerebral autoregulation in women admitted to the high-risk obstetrics&#xD;
      unit with postpartum hypertension. The investigators will then pilot this protocol in 10&#xD;
      patients with high-risk neurological features, such as headache.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Maternal neurological complications are a leading cause of postpartum severe maternal&#xD;
      morbidity and maternal mortality (SMM/MM). The lack of biomarkers to identify women at&#xD;
      highest risk of these rare, but devastating postpartum complications, including stroke,&#xD;
      seizures, and posterior reversible encephalopathy syndrome, has impeded efforts to prevent&#xD;
      neurological SMM/MM.&#xD;
&#xD;
      Impaired cerebral autoregulation may be such a biomarker. Preliminary results using&#xD;
      transcranial Doppler (TCD) based techniques to quantify cerebral autoregulation have&#xD;
      demonstrated severely impaired cerebral autoregulation in the postpartum period in some&#xD;
      women. However, TCD is operator dependent, and cannot be used for extended monitoring due to&#xD;
      discomfort. In contrast, near-infrared spectroscopy (NIRS) is fully automated and can be&#xD;
      continued for hours at the bedside. Identifying personalized blood pressure (BP) targets&#xD;
      using NIRS has been shown to improve outcomes in acute stroke patients, another population&#xD;
      with impaired cerebral autoregulation. However, this method has not been applied in&#xD;
      postpartum women.&#xD;
&#xD;
      This is a single center feasibility study that will include up to 10 women. Postpartum women&#xD;
      admitted to the obstetrics high-risk stepdown unit for management of postpartum hypertension&#xD;
      will be eligible for this study. Informed consent will be obtained from participants prior to&#xD;
      enrollment in the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Oxygenated hemoglobin concentration</measure>
    <time_frame>Continuously collected for up to 24 hours</time_frame>
    <description>The Edwards HemoSphere system with ForeSight Elite NIRS component (Edwards LifeSciences) will be used to monitor oxygenated and deoxygenated hemoglobin concentrations. Two adhesive NIRS probes will be placed on the frontotemporal scalp covering the cortex, usually supplied by the middle cerebral artery.&#xD;
[Describe how the concentration will be obtained, the range of anticipated concentrations, and how to interpret the concentrations - eg, higher concentrations indicate ...]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Deoxygenated hemoglobin concentration</measure>
    <time_frame>Continuously collected for up to 24 hours</time_frame>
    <description>The Edwards HemoSphere system with ForeSight Elite NIRS component (Edwards LifeSciences) will be used to monitor oxygenated and deoxygenated hemoglobin concentrations. Two adhesive NIRS probes will be placed on the frontotemporal scalp covering the cortex, usually supplied by the middle cerebral artery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure (BP)</measure>
    <time_frame>Continuously collected for up to 24 hours</time_frame>
    <description>Continuous non-invasive BP monitoring will be utilized (ClearSight finger cuff system, Edwards LifeSciences).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Preeclampsia</condition>
  <condition>Hypertension in Pregnancy</condition>
  <arm_group>
    <arm_group_label>Post-delivery preeclampsia patients</arm_group_label>
    <description>Women admitted to the high-risk unit(s) with elevated blood pressure and neurological symptoms, such as headache, after delivery.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Study participants will be recruited from the high-risk inpatient obstetrics unit at&#xD;
        NewYork-Presbyterian Hospital/Columbia University Irving Medical Center. Women who have&#xD;
        given birth within the previous 12 weeks and are admitted to the high-risk inpatient&#xD;
        obstetrics unit for management of hypertension will be screened.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women who have given birth within the previous 12 weeks&#xD;
&#xD;
          -  Admitted to the high-risk inpatient obstetrics unit for management of hypertension&#xD;
&#xD;
          -  With headache or other neurological symptoms such as vision changes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute ischemic stroke&#xD;
&#xD;
          -  Intracerebral or subarachnoid hemorrhage&#xD;
&#xD;
          -  Eclamptic seizures&#xD;
&#xD;
          -  Any other neurological complication requiring transfer to the neurological intensive&#xD;
             care unit or stroke stepdown unit&#xD;
&#xD;
          -  History of Reynaud's syndrome&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eliza Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eliza C. Miller, MD</last_name>
    <phone>212-305-8389</phone>
    <email>ecm2137@cumc.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Noora C. Haghighi</last_name>
    <phone>212-305-8389</phone>
    <email>nh2716@cumc.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center / NewYork-Presbyterian Hospital (NYP)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eliza Miller, MD</last_name>
      <phone>212-305-8389</phone>
      <email>ecm2137@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Noora Haghighi</last_name>
      <phone>212-305-8389</phone>
      <email>nh2716@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Eliza Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.cdc.gov/reproductivehealth/maternalinfanthealth/pmss.html</url>
    <description>Pregnancy Mortality Surveillance System (Centers for Disease Control). Accessed February 14, 2019</description>
  </link>
  <reference>
    <citation>Petersen NH, Silverman A, Strander SM, Kodali S, Wang A, Sansing LH, Schindler JL, Falcone GJ, Gilmore EJ, Jasne AS, Cord B, Hebert RM, Johnson M, Matouk CC, Sheth KN. Fixed Compared With Autoregulation-Oriented Blood Pressure Thresholds After Mechanical Thrombectomy for Ischemic Stroke. Stroke. 2020 Mar;51(3):914-921. doi: 10.1161/STROKEAHA.119.026596. Epub 2020 Feb 12.</citation>
    <PMID>32078493</PMID>
  </reference>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 1, 2021</study_first_submitted>
  <study_first_submitted_qc>December 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2021</study_first_posted>
  <last_update_submitted>December 1, 2021</last_update_submitted>
  <last_update_submitted_qc>December 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Eliza Miller</investigator_full_name>
    <investigator_title>Assistant Professor of Neurology in the Division of Stroke and Cerebrovascular Disease</investigator_title>
  </responsible_party>
  <keyword>Near-infrared spectroscopy (NIRS)</keyword>
  <keyword>Preeclampsia</keyword>
  <keyword>Pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Hypertension, Pregnancy-Induced</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

